175 related articles for article (PubMed ID: 11940107)
1. Does insulin lispro preserve the physiological defences to hypoglycaemia during intensive insulin therapy with a conventional basal bolus regimen?
Heller SR; Amiel SA; Evans ML; Kong MF; Macdonald IA; Peacey SR
Diabetes Obes Metab; 2002 Mar; 4(2):106-12. PubMed ID: 11940107
[TBL] [Abstract][Full Text] [Related]
2. Better long-term glycaemic control with the basal insulin glargine as compared with NPH in patients with Type 1 diabetes mellitus given meal-time lispro insulin.
Porcellati F; Rossetti P; Pampanelli S; Fanelli CG; Torlone E; Scionti L; Perriello G; Bolli GB
Diabet Med; 2004 Nov; 21(11):1213-20. PubMed ID: 15498088
[TBL] [Abstract][Full Text] [Related]
3. Effects of multiple daily injection therapy with Humalog mixtures versus separately injected insulin lispro and NPH insulin in adults with type I diabetes mellitus.
Roach P; Bai S; Charbonnel B; Consoli A; Taboga C; Tiengo A; Bolli G;
Clin Ther; 2004 Apr; 26(4):502-10. PubMed ID: 15189747
[TBL] [Abstract][Full Text] [Related]
4. Intensive replacement of basal insulin in patients with type 1 diabetes given rapid-acting insulin analog at mealtime: a 3-month comparison between administration of NPH insulin four times daily and glargine insulin at dinner or bedtime.
Rossetti P; Pampanelli S; Fanelli C; Porcellati F; Costa E; Torlone E; Scionti L; Bolli GB
Diabetes Care; 2003 May; 26(5):1490-6. PubMed ID: 12716810
[TBL] [Abstract][Full Text] [Related]
5. Glargine is superior to neutral protamine Hagedorn for improving glycated haemoglobin and fasting blood glucose levels during intensive insulin therapy.
Fulcher GR; Gilbert RE; Yue DK
Intern Med J; 2005 Sep; 35(9):536-42. PubMed ID: 16105155
[TBL] [Abstract][Full Text] [Related]
6. Improved glycaemic control with insulin glargine plus insulin lispro: a multicentre, randomized, cross-over trial in people with Type 1 diabetes.
Ashwell SG; Amiel SA; Bilous RW; Dashora U; Heller SR; Hepburn DA; Shutler SD; Stephens JW; Home PD
Diabet Med; 2006 Mar; 23(3):285-92. PubMed ID: 16492212
[TBL] [Abstract][Full Text] [Related]
7. Improvement of blood glucose control in Type 1 diabetic patients treated with lispro and multiple NPH injections.
Colombel A; Murat A; Krempf M; Kuchly-Anton B; Charbonnel B
Diabet Med; 1999 Apr; 16(4):319-24. PubMed ID: 10220206
[TBL] [Abstract][Full Text] [Related]
8. Optimization of evening insulin dose in patients using the short-acting insulin analog lispro.
Ahmed AB; Mallias J; Home PD
Diabetes Care; 1998 Jul; 21(7):1162-6. PubMed ID: 9653613
[TBL] [Abstract][Full Text] [Related]
9. Basal-bolus insulin therapy in Type 1 diabetes: comparative study of pre-meal administration of a fixed mixture of insulin lispro (50%) and neutral protamine lispro (50%) with human soluble insulin.
Herz M; Arora V; Sun B; Ferguson SC; Bolli GB; Frier BM
Diabet Med; 2002 Nov; 19(11):917-23. PubMed ID: 12421428
[TBL] [Abstract][Full Text] [Related]
10. The effect of the insulin analog lispro on nighttime blood glucose control in type 1 diabetic patients.
Ahmed AB; Home PD
Diabetes Care; 1998 Jan; 21(1):32-7. PubMed ID: 9538967
[TBL] [Abstract][Full Text] [Related]
11. Additional lunchtime basal insulin during insulin lispro intensive therapy in a randomized, multicenter, crossover study in adults : a real-life design.
Stades AM; Hoekstra JB; van den Tweel I; Erkelens DW; Holleman F;
Diabetes Care; 2002 Apr; 25(4):712-7. PubMed ID: 11919130
[TBL] [Abstract][Full Text] [Related]
12. Long-term intensive treatment of type 1 diabetes with the short-acting insulin analog lispro in variable combination with NPH insulin at mealtime.
Lalli C; Ciofetta M; Del Sindaco P; Torlone E; Pampanelli S; Compagnucci P; Cartechini MG; Bartocci L; Brunetti P; Bolli GB
Diabetes Care; 1999 Mar; 22(3):468-77. PubMed ID: 10097931
[TBL] [Abstract][Full Text] [Related]
13. Italian multicentre study of intensive therapy with insulin lispro in 1184 patients with Type 1 diabetes.
Valle D; Santoro D; Bates P; Scarpa L;
Diabetes Nutr Metab; 2001 Jun; 14(3):126-32. PubMed ID: 11476359
[TBL] [Abstract][Full Text] [Related]
14. Randomized cross-over trial of insulin glargine plus lispro or NPH insulin plus regular human insulin in adolescents with type 1 diabetes on intensive insulin regimens.
Murphy NP; Keane SM; Ong KK; Ford-Adams M; Edge JA; Acerini CL; Dunger DB
Diabetes Care; 2003 Mar; 26(3):799-804. PubMed ID: 12610040
[TBL] [Abstract][Full Text] [Related]
15. A randomized, controlled trial comparing insulin lispro with human soluble insulin in patients with Type 1 diabetes on intensified insulin therapy. The UK Trial Group.
Gale EA
Diabet Med; 2000 Mar; 17(3):209-14. PubMed ID: 10784225
[TBL] [Abstract][Full Text] [Related]
16. Symptomatic and physiological responses to hypoglycaemia induced by human soluble insulin and the analogue Lispro human insulin.
McCrimmon RJ; Frier BM
Diabet Med; 1997 Nov; 14(11):929-36. PubMed ID: 9400916
[TBL] [Abstract][Full Text] [Related]
17. A 16-week comparison of the novel insulin analog insulin glargine (HOE 901) and NPH human insulin used with insulin lispro in patients with type 1 diabetes.
Raskin P; Klaff L; Bergenstal R; Hallé JP; Donley D; Mecca T
Diabetes Care; 2000 Nov; 23(11):1666-71. PubMed ID: 11092290
[TBL] [Abstract][Full Text] [Related]
18. Insulin detemir lowers the risk of hypoglycaemia and provides more consistent plasma glucose levels compared with NPH insulin in Type 1 diabetes.
Kølendorf K; Ross GP; Pavlic-Renar I; Perriello G; Philotheou A; Jendle J; Gall MA; Heller SR
Diabet Med; 2006 Jul; 23(7):729-35. PubMed ID: 16842476
[TBL] [Abstract][Full Text] [Related]
19. Symptomatic and counterregulatory hormonal responses to acute hypoglycaemia induced by insulin aspart and soluble human insulin in Type 1 diabetes.
Frier BM; Ewing FM; Lindholm A; Hylleberg B; Kanc K
Diabetes Metab Res Rev; 2000; 16(4):262-8. PubMed ID: 10934454
[TBL] [Abstract][Full Text] [Related]
20. Glycaemic control and hypoglycaemia in children, adolescents and young adults with unstable type 1 diabetes mellitus treated with insulin glargine or intermediate-acting insulin.
Herwig J; Scholl-Schilling G; Böhles H
J Pediatr Endocrinol Metab; 2007 Apr; 20(4):517-25. PubMed ID: 17550216
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
